Whiteaker J, Zhao L, Schoenherr R, Huang D, Kennedy J, Ivey R
Sci Data. 2024; 11(1):682.
PMID: 38918394
PMC: 11199596.
DOI: 10.1038/s41597-024-03467-x.
Whiteaker J, Zhao L, Schoenherr R, Huang D, Lundeen R, Voytovich U
Front Oncol. 2023; 13:1168710.
PMID: 37205196
PMC: 10185886.
DOI: 10.3389/fonc.2023.1168710.
Whiteaker J, Wang T, Zhao L, Schoenherr R, Kennedy J, Voytovich U
Cancers (Basel). 2021; 13(15).
PMID: 34359745
PMC: 8345163.
DOI: 10.3390/cancers13153843.
Kennedy J, Whiteaker J, Kennedy L, Bosch D, Lerch M, Schoenherr R
Clin Chem. 2021; 67(7):1008-1018.
PMID: 34136904
PMC: 8260184.
DOI: 10.1093/clinchem/hvab047.
Collins C, Yi F, Dayuha R, Duong P, Horslen S, Camarata M
Gastroenterology. 2021; 160(7):2367-2382.e1.
PMID: 33640437
PMC: 8243898.
DOI: 10.1053/j.gastro.2021.02.052.
A dataset describing a suite of novel antibody reagents for the RAS signaling network.
Schoenherr R, Huang D, Voytovich U, Ivey R, Kennedy J, Saul R
Sci Data. 2019; 6(1):160.
PMID: 31467290
PMC: 6715692.
DOI: 10.1038/s41597-019-0166-7.
Rapid Multiplexed Proteomic Screening for Primary Immunodeficiency Disorders From Dried Blood Spots.
Collins C, Chang I, Jung S, Dayuha R, Whiteaker J, Segundo G
Front Immunol. 2018; 9:2756.
PMID: 30564228
PMC: 6288356.
DOI: 10.3389/fimmu.2018.02756.
Clinical potential of mass spectrometry-based proteogenomics.
Zhang B, Whiteaker J, Hoofnagle A, Baird G, Rodland K, Paulovich A
Nat Rev Clin Oncol. 2018; 16(4):256-268.
PMID: 30487530
PMC: 6448780.
DOI: 10.1038/s41571-018-0135-7.
Targeted mass spectrometry enables robust quantification of FANCD2 mono-ubiquitination in response to DNA damage.
Whiteaker J, Zhao L, Ivey R, Sanchez-Bonilla M, Moore H, Schoenherr R
DNA Repair (Amst). 2018; 65:47-53.
PMID: 29605812
PMC: 5911425.
DOI: 10.1016/j.dnarep.2018.03.003.
A Multiplexed Mass Spectrometry-Based Assay for Robust Quantification of Phosphosignaling in Response to DNA Damage.
Whiteaker J, Zhao L, Saul R, Kaczmarczyk J, Schoenherr R, Moore H
Radiat Res. 2018; 189(5):505-518.
PMID: 29474155
PMC: 5939939.
DOI: 10.1667/RR14963.1.
Advancing the immunoaffinity platform AFFIRM to targeted measurements of proteins in serum in the pg/ml range.
Sall A, Corbee D, Vikstrom S, Ottosson F, Persson H, Waldemarson S
PLoS One. 2018; 13(2):e0189116.
PMID: 29438379
PMC: 5810979.
DOI: 10.1371/journal.pone.0189116.
Peptide and Protein Quantification Using Automated Immuno-MALDI (iMALDI).
Li H, Popp R, Frohlich B, Chen M, Borchers C
J Vis Exp. 2017; (126).
PMID: 28872133
PMC: 5614345.
DOI: 10.3791/55933.
Development of a Multiplexed Assay for Oral Cancer Candidate Biomarkers Using Peptide Immunoaffinity Enrichment and Targeted Mass Spectrometry.
Hsiao Y, Chi L, Chien K, Chiang W, Chen S, Chuang Y
Mol Cell Proteomics. 2017; 16(10):1829-1849.
PMID: 28821604
PMC: 5629267.
DOI: 10.1074/mcp.RA117.000147.
Optimized Protocol for Quantitative Multiple Reaction Monitoring-Based Proteomic Analysis of Formalin-Fixed, Paraffin-Embedded Tissues.
Kennedy J, Whiteaker J, Schoenherr R, Yan P, Allison K, Shipley M
J Proteome Res. 2016; 15(8):2717-28.
PMID: 27462933
PMC: 5017241.
DOI: 10.1021/acs.jproteome.6b00245.
Contributions of immunoaffinity chromatography to deep proteome profiling of human biofluids.
Wu C, Duan J, Liu T, Smith R, Qian W
J Chromatogr B Analyt Technol Biomed Life Sci. 2016; 1021:57-68.
PMID: 26868616
PMC: 4862894.
DOI: 10.1016/j.jchromb.2016.01.015.
Key factors influencing ADME properties of therapeutic proteins: A need for ADME characterization in drug discovery and development.
Tibbitts J, Canter D, Graff R, Smith A, Khawli L
MAbs. 2015; 8(2):229-45.
PMID: 26636901
PMC: 4966629.
DOI: 10.1080/19420862.2015.1115937.
Advances in Proteomic Technologies and Its Contribution to the Field of Cancer.
Mesri M
Adv Med. 2015; 2014:238045.
PMID: 26556407
PMC: 4590950.
DOI: 10.1155/2014/238045.
Antibody-Coupled Magnetic Beads Can Be Reused in Immuno-MRM Assays To Reduce Cost and Extend Antibody Supply.
Zhao L, Whiteaker J, Voytovich U, Ivey R, Paulovich A
J Proteome Res. 2015; 14(10):4425-31.
PMID: 26302155
PMC: 5017239.
DOI: 10.1021/acs.jproteome.5b00290.
Immunocapture-Selected Reaction Monitoring Screening Facilitates the Development of ELISA for the Measurement of Native TEX101 in Biological Fluids.
Korbakis D, Brinc D, Schiza C, Soosaipillai A, Jarvi K, Drabovich A
Mol Cell Proteomics. 2015; 14(6):1517-26.
PMID: 25813379
PMC: 4458717.
DOI: 10.1074/mcp.M114.047571.
Anti-peptide monoclonal antibodies generated for immuno-multiple reaction monitoring-mass spectrometry assays have a high probability of supporting Western blot and ELISA.
Schoenherr R, Saul R, Whiteaker J, Yan P, Whiteley G, Paulovich A
Mol Cell Proteomics. 2014; 14(2):382-98.
PMID: 25512614
PMC: 4350033.
DOI: 10.1074/mcp.O114.043133.